FEMLYV (Ethinyl Estradiol; Norethindrone Acetate) Patent Expiration, LOE Window & CMS Spending

FEMLYV (Ethinyl Estradiol; Norethindrone Acetate) by Millicent Manufacturing Pr: FDA Orange Book core substance LOE 2041-06-24, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMillicent Manufacturing Pr
FDA Application & PathwayN218718 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-06-24
Last Listed Patent or Exclusivity Date2041-06-24
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel